Why Indian Parents Must Plan the Full UG-to-Specialist Journey — Not Just the MBBS Admission

An evidence-based guide for parents of Class 11–12 PCB
students and NEET aspirants, built on official data from AAMC, NRMP, GMC, AMC,
MCNZ, NMC, NBEMS, UCAS and the Ministry of External Affairs

Every year, hundreds of thousands of Indian families make a single, high-stakes decision where to study MBBS using a narrow set of questions: which country, which university, what fees, what FMGE pass rate. This article argues that this is the wrong framing entirely. The real decision is not “where should my child study MBBS?” but “can my child become a licensed, practising specialist doctor, and where?” That second question requires looking simultaneously at undergraduate admission, licensing examinations, internship availability, postgraduate residency competition, specialist registration, visa pathways, and the option to return to India because in every country examined here, the bottleneck is not getting into medical school. It is getting through to independent specialist practice afterward.

Key Statistics at a Glance

Metric	Figure	Source / Year
NEET-UG 2025 candidates qualified	~12.36 lakh (1,236,000) qualified out of ~22 lakh appeared	MCC/NTA, 2025
Total MBBS seats in India	1,28,976 across 818 colleges (Mar 2026)	NMC/MCC, 2026
MBBS seats vs NEET qualifiers	Roughly 1 seat per 9-10 qualified candidates	MCC, NMC, 2025
US MD applicants (2025)	54,699 total; only 1,390 had legal residence outside the US	AAMC, 2025
US international MD matriculants	105 out of 1,390 international applicants (~7.6%)	AAMC, 2025
US Non-citizen IMG Match rate (2026)	56.4% PGY-1 match rate, lowest in 5 years	NRMP, 2026
UK international medical school seats	~500 places for international students vs ~7,100 for home students	UCAT/MSC data, 2025
UK PLAB-to-training-post conversion	Only 2.4% of 2024 PLAB Part 2 passers secured an NHS training post that year	GMC FOI analysis, 2025
India: FMGE pass rate (recent sessions)	Ranged ~18.6% to 29.6% (June 2024-Dec 2025 sessions)	NBEMS, 2024-25
Indian students abroad (all subjects, 2024)	~13.36 lakh; medical education a major driver of mobility to Central/East Asia	MEA, 2024

Source: AAMC, NRMP, GMC, NBEMS, MCC, MEA — Figures are the most recent publicly released official data as of mid-2026 and will be superseded by future annual releases.

How Competitive Is Undergraduate Admission in the USA?

Before even reaching medical school, an international student must first be admitted to an undergraduate college (or apply via the 4-year MD-only route used by very few schools). The SAT and ACT are gateway exams into undergraduate study, not medicine; they have no role in MD admissions, which run through a separate process (AMCAS) after a bachelor’s degree. The undergraduate funnel itself is large: the US enrols hundreds of thousands of international students annually across all fields, and standardised test volumes (SAT, ACT) run into the millions of test-takers per cycle when domestic and international candidates are combined. None of this volume translates into medical school capacity — undergraduate admission and medical school admission are governed by entirely separate, sequential processes, and clearing the first does not meaningfully improve odds at the second.

Note on data availability: College Board and ACT do not publish a single authoritative “international SAT/ACT takers” figure broken out by intended major; for this reason this article does not assign a specific number to that metric and instead focuses on the medical school funnel, where AAMC publishes verified figures.

Medical School in the USA: The Real Bottleneck

AAMC data for the 2025 entering class shows the scale of competition clearly. A total of 54,699 people applied to US MD-granting medical schools in 2025, a 5.3% increase over 2024, and 23,440 were accepted into the incoming class the largest matriculant class on record, pushing total US MD enrolment past 100,000 for the first time. The mean MCAT score among matriculants was 512.1 and the mean undergraduate GPA was 3.81, reflecting an extremely high academic bar even for domestic, US-citizen applicants.

For international families, the more important number sits inside this total: of the 54,699 applicants in 2025, only 1,390 reported a legal residence outside the United States, an increase of 10.8% over 2024 — and of those 1,390 international applicants, only 105 matriculated, a decline of 19.2% from the prior year. That is roughly a 7.6% matriculation rate for international applicants into a system where the great majority of seats, funding structures (federal loans, scholarships) and institutional missions are built around US citizens and permanent residents. The overwhelming majority of the roughly 156 MD-granting medical schools in the US either do not consider international applicants at all or admit only a handful per cohort, and require proof of ability to self-fund the full cost of attendance (commonly USD 250,000-350,000+ across four years) since international students are ineligible for US federal financial aid.

US Medical School Funnel (2025 cycle)	Figure
Total MD applicants	54,699
Total MD matriculants	23,440
Overall applicant-to-matriculant rate	~42.9%
Applicants with legal residence outside the US	1,390
International matriculants	105
International applicant-to-matriculant rate	~7.6%

Source: AAMC, “U.S. medical schools enroll record number of students in 2025,” AAMC News, Dec 2025; AAMC FACTS Tables.

Medicine in the UK: A Tightly Capped System

UK medical school admissions are shaped by direct government workforce planning. Applications for 2026 entry rose to 25,770 by the UCAS October 2025 deadline, a 10.4% increase on the previous cycle, while government-funded places have grown only marginally — the Office for Students has capped Medicine places in England at around 8,126 for 2025-26. The UCAT (University Clinical Aptitude Test) is the standard admissions test used by most UK medical schools; BMAT was discontinued from 2024 entry onward.

Critically for Indian families, most UCAT Consortium medical school places are reserved for UK “home” students under NHS workforce-funding rules. Industry analyses of UCAT Consortium and UCAS data place the total pool of places genuinely open to international applicants at roughly 500 across the whole of the UK, compared with approximately 7,100 home-fee places — meaning international candidates compete for under 7% of total UK medical school capacity, and that capacity is concentrated in a handful of schools (newer private-model courses such as Brunel, and overseas-campus programmes such as QMUL Malta and UCLan, which admit a higher proportion of overseas students but are non-NHS-funded and charge full international fees, commonly £40,000-£75,000 per year).

UK Medicine Funnel (2025/26 cycle)	Figure
Total UCAS Medicine applicants (2026 entry, Oct 2025 deadline)	25,770
England OfS-capped Medicine places (2025-26)	~8,126
Estimated UK-wide international (overseas-fee) places	~500
Estimated UK-wide home-fee places	~7,100
Implied international applicant-to-place ratio	Many multiples higher than home-student ratio (varies sharply by school: ~4% at Edinburgh vs ~38% at Queen’s Belfast)

Source: UCAS Medicine application statistics, Oct 2025 deadline; Office for Students place caps 2025-26; UCAT Consortium / Medical Schools Council international place estimates, 2025.

Australia: Internship and Specialist Training Bottlenecks

Australia uses the UCAT ANZ for most undergraduate-entry medical programmes and GAMSAT for graduate-entry programmes, with a small, fixed number of Commonwealth-supported and full-fee international places per university each year. For international medical graduates who complete their MBBS overseas (rather than in Australia), the relevant route is the Australian Medical Council (AMC) Standard Pathway, which leads to general registration via the Medical Board of Australia (Ahpra).

The AMC’s own published guidance is explicit that IMGs without an Australian or New Zealand internship face a structural disadvantage: priority for accredited intern positions in Australia is given to Australian medical graduates, and an internal AMC survey found that of IMGs who completed the Standard Pathway, 77% took more than a year to do so, with the dominant causes of delay being the AMC Clinical Examination and securing the supervised employment needed to apply for limited registration. A separate peer-reviewed mixed-methods study of 220+ IMGs in Australia found that even after successfully clearing AMC examinations, more than two-thirds expressed interest in further specialist training, but only 47% believed their likelihood of acceptance into a training programme was high — and 11.3% of working IMGs in the sample had moved into non-clinical roles rather than continuing in direct patient care. Australia also imposes a so-called 10-year moratorium under federal legislation requiring many IMGs to work in designated workforce-shortage (often rural/regional) areas for up to a decade before they can practise freely in metropolitan areas, which the same study’s respondents frequently described as professionally isolating.

This does not mean Australia is a poor destination — its remuneration, lifestyle and eventual permanent residency pathway are genuinely strong once a doctor is established but it underscores that admission to an MBBS programme abroad does not, by itself, secure a path into the Australian medical workforce; intern places, AMC examinations, and specialist college acceptance are each separate, competitive checkpoints.

India: The Domestic Funnel and the Outflow It Creates

India’s own undergraduate medical funnel is the starting point for understanding why families look abroad at all. In NEET-UG 2025, roughly 22 lakh candidates appeared and approximately 12.36 lakh qualified, competing for a national MBBS capacity that stood at 1,28,976 seats across 818 medical colleges as of March 2026 (45.4% government, 42.8% private, with the balance in deemed universities, AIIMS and other Institutes of National Importance). Put simply, even among NEET-qualified candidates, roughly only 1 in 9 to 1 in 10 secures an MBBS seat in India in a given cycle — and government seats, which carry the lowest fees, are an even smaller subset of that already-narrow funnel.

This domestic scarcity, combined with private and deemed-university fees in India that can range from roughly ₹50 lakh to over ₹1.5 crore for the full MBBS course, has driven a sustained outflow of Indian students to medical schools abroad. Ministry of External Affairs data shows the total population of Indian students studying abroad across all subjects reached approximately 13.36 lakh in 2024, with medical education identified by the Ministry as a primary driver of student mobility specifically to East and Central Asian destinations Georgia (16,093 Indian students across all courses), the Philippines (9,665), China (8,580) and Uzbekistan (4,100) feature prominently among destination countries with large medical-student cohorts, alongside Russia, Bangladesh, Nepal, Kazakhstan, Kyrgyzstan, Armenia, Azerbaijan and Belarus as established low-cost MBBS destinations. The collapse of Indian enrolment in Ukraine (from 11,987 in 2023 to 2,510 in 2024, reflecting the ongoing conflict) illustrates how exposed this pathway is to geopolitical risk, not just academic risk.

The Hidden Cost Nobody Talks About

The MBBS-abroad conversation in India typically ends at “degree completion.” The harder, more important question is what happens after: can the graduate actually become a licensed, practising doctor in India, in the country they studied in, or anywhere?

Clearing FMGE/NExT to practise in India

For the large majority of Indian students who study MBBS abroad and intend to return and practise in India, the Foreign Medical Graduate Examination (FMGE), administered by the National Board of Examinations in Medical Sciences (NBEMS), is the mandatory gate. FMGE pass rates have been volatile and consistently low: 20.89% in June 2024, rising to 29.62% in December 2024 (one of the strongest December results in three years), then falling back to 18.61% in June 2025 before recovering to 23.9% in December 2025. Averaged across the last five years, the pass rate has hovered between roughly 18% and 30% per session, meaning the clear majority of candidates do not clear FMGE on a given attempt, though there is no cap on the number of attempts. Pass rates vary enormously by country and university of origin — NBEMS country-wise data for 2024 shows Georgia at the higher end (35.65% nationally, with leading universities exceeding 60-80%), Russia around 29.5%, Bangladesh 26.8-32.4%, the Philippines 18.5-24%, and several Central Asian and East European destinations (including parts of Russia, China, Ukraine, Armenia, Azerbaijan, Belarus and Uzbekistan) reporting single-digit to mid-teens pass rates in various analyses — underscoring that the choice of country and even specific university materially affects the odds of ever practising legally in India.

The population that never becomes licensed

Quantifying precisely how many Indian MBBS-abroad graduates never obtain an Indian licence to practise is genuinely difficult, and this article does not invent a number where official data does not exist. What can be triangulated responsibly from available data: FMGE/NExT candidate volumes have grown from roughly 22,000-30,000 per session in 2021 to 36,000-44,000 per session in 2024-2025, reflecting the rising scale of MBBS-abroad enrolment several years earlier; pass rates across this period have rarely exceeded 30%; and FMGE has no enrolment cap, meaning repeat attempts by previously unsuccessful candidates are folded into each session’s totals, which makes it difficult to isolate a clean “never passed” cohort from published session-by-session data alone. NBEMS and NMC do not publish a longitudinal cohort-tracking figure (i.e., “of everyone who attempted FMGE in 2018-2020, what share eventually passed by 2025”) in the public domain. What is defensible to state is this: based on five years of session-level pass rates clustering between roughly 18% and 30%, a substantial share of FMGE/NExT candidates — plausibly a majority across a typical cohort’s lifetime attempts, though this cannot be stated as a precise verified figure — face a multi-year, multi-attempt struggle to obtain Indian licensure, and some proportion never succeeds. Parents should treat any specific “X% of MBBS-abroad graduates never get licensed” claim circulating in coaching-industry marketing with scepticism unless it cites a primary NBEMS/NMC cohort study, because no such study is currently public.

Cannot obtain residency abroad either

The same graduates who struggle with FMGE often also face a steep climb if they instead try to build a career in the country they studied in, or pivot to the US, UK or Australia. As shown above, non-US-citizen IMGs achieved only a 56.4% PGY-1 Match rate in the US in 2026 (and the true “full funnel” match rate — counting those who never received an interview and didn’t submit a rank list — is estimated by IMG-focused analysts at closer to 49%); UK PLAB-passers secured NHS training posts at a rate of just 2.4% in their first year; and Australian and New Zealand IMG pathways are gated by internship scarcity and lengthy AMC/MCNZ assessment processes. A graduate who does not clear these hurdles, and also does not clear FMGE, can find themselves with a medical degree that is formally unrecognised for independent clinical practice anywhere.

10.4 The shift to non-clinical careers

Anecdotal and survey evidence (including the Australian IMG study cited above, which found 11.3% of working IMGs had moved into non-clinical roles) suggests that a meaningful share of MBBS-abroad graduates who cannot complete a licensing pathway pivot into adjacent fields: medical writing, healthcare consulting, pharmaceutical and medical-device industry roles, health-tech, public health administration, medical education/coaching, or further study (MBA, MPH, healthcare management). This is not necessarily a failure outcome — some graduates pursue these paths by choice but for families who invested ₹40 lakh-₹1.5 crore specifically to produce a practising doctor, an unplanned pivot to a non-clinical career represents a significant, and avoidable, mismatch between investment and outcome.

Why Undergraduate Planning Alone Is Dangerous

The standard parent questionnaire when choosing a medical school looks like this: which country, which university, what are the fees, what is the FMGE pass rate. Each of these is necessary but not sufficient. The data above shows why a different, longer questionnaire is required:

• Can my child become a licensed doctor — in India, in the country of study, or both — and on what realistic timeline and at what realistic probability, given the specific university’s track record (not just the country average)?
• Can my child obtain postgraduate training (residency/registrar position) in a country where they actually want to live and work, given that internship and residency places are the binding constraint almost everywhere, not undergraduate seats?
• Can my child enter residency in a reasonable number of application cycles, and does our family have the financial runway to support several unmatched cycles if the first attempt fails (which, per NRMP data, happens to roughly 4 in 10 non-US IMG applicants even in a “good” year)?
• Can my child work in their intended country long enough, and under what visa category, to reach specialist registration — and what happens to their visa status if they do not match or do not secure a training post on the first attempt?
• If the international pathway stalls, can my child return to India and practise — which depends entirely on FMGE/NExT, a gate with a historical pass rate below 30% in most sessions?
• Can my child realistically become a specialist (not just a general practitioner) in their chosen country, given subspecialty-level competition that is often sharper than entry-level competition (for example, US fellowship Match data shows wide variation in the share of positions filled by IMGs by subspecialty)?

None of these questions can be answered by looking at a university brochure or a single country-level FMGE statistic. They require modelling the entire pathway — UG, licensing, internship, PG training, specialist registration, and a credible fallback plan before the first admission offer is accepted.

Comparing the Entire Career Journey

The table below compares the full pathway, not just admission, across India and the four destinations covered in this article. Timelines and costs are approximate ranges based on the sources cited throughout this article and are illustrative, not quotes for any specific institution.

Stage	India (MBBS in India)	USA (IMG route)	UK (IMG route)	Australia (IMG route)	New Zealand (IMG route)
UG entrance exam	NEET-UG	Foreign MBBS entry exam (varies by country) + later USMLE	Foreign MBBS entry exam + later PLAB/UKMLA	Foreign MBBS entry exam + later AMC exams	Foreign MBBS entry exam + later NZREX/CAP
UG degree length	5.5 yrs (incl. internship)	4-6 yrs (country dependent)	4-6 yrs (country dependent)	4-6 yrs (country dependent)	4-6 yrs (country dependent)
Licensing exam to practise locally	N/A (Indian degree)	USMLE Step 1, 2 CK, (2 CS where applicable)	PLAB 1 & 2 (now UKMLA-aligned)	AMC CAT MCQ + Clinical Exam/WBA	NZREX Clinical or Competent Authority route
Internship/residency entry	Mandatory rotating internship, India	NRMP Match (56.4% PGY-1 rate for non-US IMGs, 2026)	Highly limited NHS training-post conversion (~2.4% of 2024 PLAB cohort in year 1)	AMC internship priority to AUS/NZ grads; IMGs often face long delays (77% take 1+ yrs)	Limited PGY1 house-officer places; competitive national allocation
Specialisation	NEET-PG → MD/MS/DNB (highly competitive)	Subspecialty fellowship Match (varies sharply by field)	Specialty training (ST) application, competitive by specialty	Specialist college acceptance, often multi-year wait	Specialist college (RACP/RACS-equivalent) registration
Return-to-India option	N/A	Requires FMGE/NExT (pass rate ~18-30% recent sessions)	Requires FMGE/NExT	Requires FMGE/NExT	Requires FMGE/NExT
Approx. total UG+licensing timeline	6-7 yrs	8-12+ yrs to independent practice	7-11+ yrs to independent practice	8-13+ yrs to independent practice	8-13+ yrs to independent practice
Approx. total cost (UG, family-funded)	₹50 lakh-₹1.5 crore (private/deemed)	₹2-3 crore+ (international fees, no federal aid)	₹2.5-5.5 crore (international fees, multi-year)	₹2-4 crore	₹1.5-3 crore
Difficulty of postgraduate entry for IMGs	Very high (limited PG seats nationally)	High (56.4% non-US-IMG Match rate, 2026)	Very high (2.4% training-post conversion, 2024 cohort)	High (internship scarcity + AMC delays)	High (small system, limited intern places)

Source: Compiled from AAMC, NRMP, ECFMG, GMC, AMC, MCNZ, NBEMS and published 2024-2026 fee/cost ranges from official university and visa-financial-requirement disclosures; costs vary materially by specific university and should be verified individually before any commitment.

Financial Analysis: Modelling the Real Investment

Parents typically budget for the MBBS degree itself. A complete financial model should include four additional layers: licensing-exam costs and prep (USMLE/PLAB/AMC exams plus structured coaching, commonly ₹5-15 lakh depending on country and number of attempts); the opportunity cost of multiple unmatched/unsuccessful cycles (each additional year before securing a training post delays the start of earning specialist-level income by a year, and in several countries requires self-funding living costs during that gap); visa and immigration costs across each country transition; and the realistic probability, drawn from the Match/registration data in this article, that more than one attempt will be needed.

Investment Scenario	Approx. Total Cost Range (illustrative)	Key Risk Factor
UG only (degree, no further plan)	₹50 lakh – ₹5.5 crore depending on country	No path to independent practice anywhere without further licensing
UG + licensing exam cleared (USMLE/PLAB/AMC etc.)	+₹5-15 lakh on top of UG cost	Licensing alone does not guarantee a training post (see Match/conversion rates above)
UG + licensing + successful residency/registrar match	+1-3 additional years of living costs if multiple cycles needed	Match/training-post rates of 50-60% (non-US IMGs) to ~2.4% (UK first-year conversion) mean repeat cycles are common, not exceptional
Opportunity cost	1-3 years of foregone specialist-level income per delayed cycle	Compounds with each unsuccessful attempt

On the return side: post-specialisation salaries vary widely by country and specialty (broadly, US specialists earn the highest absolute compensation, followed by Australia and the UK, with India offering lower absolute pay but a dramatically lower cost base and no further licensing risk once NEET-PG/DNB is cleared). A meaningful ROI calculation must discount expected income by the realistic probability of reaching specialist status within a defined timeframe not assume a 100% success rate, which the Match, PLAB-conversion and AMC-pathway data above show is not the historical norm for IMGs in any of the four countries examined.

Common Mistakes Parents Make

• Choosing the lowest-cost university without checking its specific FMGE/USMLE/PLAB/AMC track record.
• Relying on advice from an admissions agent whose income depends on the student enrolling at a specific partner university, rather than on independent, university-agnostic guidance.
• Ignoring postgraduate planning entirely until after the UG degree is complete, by which point the choice of country and university (which materially affects PG odds) can no longer be changed.
• Assuming internship is guaranteed; in Australia, the UK and New Zealand, internship/foundation positions are allocated competitively and are not automatic for IMGs.
• Underestimating licensing-exam difficulty and treating it as a formality rather than a multi-year, multi-attempt undertaking with the pass rates shown in this article.
• Ignoring residency/registrar competitiveness, including the fact that non-US-citizen and visa-requiring applicants face measurably lower match/placement rates than citizens or permanent residents in the same systems.
• Ignoring visa pathway complexity, including what happens to status if a Match or training-post application is unsuccessful in a given cycle.
• Ignoring language and cultural-context requirements (e.g., UCAT/PLAB content is built around UK clinical and cultural scenarios that are unfamiliar to many international candidates without targeted preparation).
• Ignoring workforce demand data in the destination country, which directly drives how many training posts and specialist vacancies actually exist (the GMC/NHS PLAB-conversion crisis above is a direct result of supply outpacing this demand).

Why Independent Career Coaching Matters More Than University Admission

Most of what is marketed in India as “study abroad counselling” for medicine is, structurally, university admissions agency work: the agency is compensated by partner universities for each enrolled student, which creates an inherent incentive to maximise enrolments rather than to maximise the student’s long-term odds of becoming a licensed, practising specialist. This is not a claim that all such agencies act in bad faith many genuinely try to place students well but the revenue model itself shapes what gets emphasised (which universities are “recommended,” how aggressively downside risk is communicated) regardless of individual intent.

Dimension	University Admission Agent	Independent Medical Career Coach
Revenue model	Commission per enrolled student, paid by partner universities	Fee paid directly by the family for advisory time
Conflict of interest	Structural — income tied to enrolment at specific partner institutions	Minimal — no payment from any university
University commissions	Receives them; influences recommendations	Receives none
Career planning scope	Typically ends at admission	Spans UG choice through licensing, residency, and specialty planning
Specialty planning	Rarely addressed	Modelled explicitly against destination-country data
Licensing guidance (USMLE/PLAB/AMC/NZREX/FMGE)	Often generic or outsourced	Central to the planning process from day one
Residency/registrar planning	Rarely addressed at UG stage	Modelled before the UG choice is finalised
Country comparison	Limited to partner-university countries	Evidence-based, across all viable destinations
Long-term mentorship	Typically ends after enrolment	Continues through licensing and residency planning
Transparency on downside risk (FMGE/Match/PLAB conversion data)	Inconsistent	Disclosed and modelled explicitly
Student-first orientation	Constrained by commission structure	Structurally aligned, since fees are not tied to any specific outcome

This is not to say career coaching guarantees a successful outcome no one can guarantee a NRMP Match, a GMC training post or an FMGE pass but a coaching relationship structurally free of university commissions is positioned to disclose the data of this article honestly, rather than to minimise it.

Why ConsultCK Exists

ConsultCK is an independent medical career coaching and mentoring practice founded by Chirag Khutia, who has 18 years of experience in medical career guidance and has visited hundreds of university campuses worldwide.

The practice exists because, as this article has shown, the undergraduate admission decision is only the first of many decision points in a medical career, and most families are never shown the data needed to evaluate the later decision points before the first one is made. ConsultCK works with students and families across the full arc of that journey: undergraduate pathway selection grounded in realistic postgraduate odds, not marketing claims; licensing-exam roadmap planning (FMGE/NExT, USMLE, PLAB, AMC, NZREX) aligned to the student’s actual destination country; research experience and CV-building guidance for residency competitiveness; elective and clinical-exposure planning; and long-term mentorship through specialty selection and residency/registrar applications, including contingency planning for the realistic possibility that a first attempt at licensing or matching does not succeed.

Frequently Asked Questions

Q1. Is MBBS abroad a bad decision?

Not inherently. The data in this article shows it is a high-variance decision whose outcome depends heavily on the specific country, university, and whether the licensing/residency pathway is planned before enrolment, not after.

Q2. What is the safest country for an Indian student to study MBBS abroad?

There is no single “safest” answer; “safety” depends on whether the goal is to return and practise in India (where university-specific FMGE pass rate matters most) or to build a career abroad (where the destination country’s IMG pathway data matters most). This article provides the framework to evaluate either goal.

Q3. What is FMGE and why does it matter so much?

FMGE (being phased toward NExT) is the mandatory NBEMS screening exam that determines whether an Indian citizen with a foreign MBBS degree may register to practise in India. Recent session pass rates have ranged roughly 18.6%-29.6% (NBEMS, 2024-2025).

Q4. Can my child clear FMGE on the first attempt?

There is no way to guarantee this. University-specific pass rates vary from under 10% to 100% in NBEMS country/university breakdowns, so the choice of institution materially affects the odds.

Q5. Is the USMLE harder than FMGE?

They test different things and aren’t directly comparable in difficulty, but USMLE Step 1/2 CK pass rates for IMGs are generally higher than FMGE’s; the much harder bottleneck for US-bound IMGs is the NRMP Match itself (56.4% PGY-1 rate for non-US-citizen IMGs in 2026).

Q6. How many international students get into US medical schools each year?

AAMC 2025 data shows just 105 matriculants among 1,390 applicants who reported legal residence outside the US — roughly a 7.6% matriculation rate, and most US MD programmes do not admit international students at all.

Q7. Do UK medical schools really have separate, smaller quotas for international students?

Yes. Industry analysis of UCAT Consortium/UCAS data estimates roughly 500 UK-wide places for international students against approximately 7,100 for home-fee students.

Q8. If my child passes PLAB, will they get an NHS training job?

Not automatically. A 2025 FOI-based analysis of GMC data found only 2.4% of the 2024 PLAB Part 2 cohort secured an NHS training post within the same year, with 79.9% not connected to any NHS employing body.

Q9. Is Australia easier for international medical graduates than the UK or US?

Australia’s AMC Standard Pathway has its own bottlenecks: priority for intern positions goes to Australian/NZ graduates, and AMC’s own data shows 77% of Standard Pathway IMGs take more than a year to complete the pathway.

Q10. What about New Zealand?

New Zealand has a small overall medical workforce and correspondingly limited intern and specialist-training capacity; it should be evaluated with the same rigour as larger destinations, not assumed to be an “easy” alternative.

Q11. How many MBBS seats does India have for NEET-UG aspirants?

As of March 2026, 1,28,976 total MBBS seats across 818 colleges, against roughly 12.36 lakh NEET-UG 2025 qualifiers — meaning the great majority of qualified candidates still do not secure a seat in India.

Q12. Should we choose a college based on the lowest fees?

Fees should be evaluated alongside the institution’s specific FMGE/licensing track record and its clinical training quality; the cheapest option is not a saving if it materially lowers the odds of ever practising.

Q13. What happens if my child cannot clear FMGE and cannot get a residency abroad either?

This is the scenario this article calls “the hidden cost”. It happens to a meaningful share of graduates, though no verified single national figure exists; many in this position transition to non-clinical healthcare-adjacent careers.

Q14. Is it better to do MD/MS in India after MBBS abroad?

NEET-PG seats in India are also highly competitive, including for FMGE-qualified graduates; this should be modelled, not assumed, before committing to the UG-abroad route.

Q15. How long does it realistically take to become a specialist as an international medical graduate?

Across the countries reviewed here, realistic timelines from school-leaving to independent specialist practice run roughly 8 to 15 years for IMGs, depending heavily on how many licensing/Match cycles are needed.

Q16. Does ConsultCK get a commission if we choose a particular university?

No. ConsultCK is an independent career coaching practice and receives no commission from any college or university.

Q17. Is an admissions agent the same as a career coach?

No. An admissions agent is typically compensated by partner universities per enrolled student; an independent career coach is compensated directly by the family and has no university-side financial incentive.

Q18. What is the single biggest planning mistake parents make?

Treating undergraduate admission as the end of the decision rather than the first of several sequential, competitive checkpoints (licensing, internship, residency, specialisation) that should all be modelled together before enrolment.

Q19. Can my child still return to India later if the international pathway doesn’t work out?

Only by clearing FMGE/NExT, which is not guaranteed and has had recent session pass rates below 30%; this should be treated as a real contingency to plan for, not an automatic fallback.

Q20. Where can I get an independent, evidence-based assessment for my child’s specific situation?

ConsultCK offers individualised career counselling sessions that model UG, licensing, and postgraduate pathways together for each student’s specific circumstances; visit consultck.in or call +91 70455 22007.